iVEAcare is focused on developing and commercializing next generation neuromodulation technology platforms to treat patients suffering from chronic diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/22/24 | $27,500,000 | Series A |
Hatteras Venture Partners Treo Ventures Vensana Capital  | undisclosed |
